Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average: 2013-2025

Historic Equity Average for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $72.0 million.

  • Enanta Pharmaceuticals' Equity Average fell 48.15% to $72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year decrease of 48.15%. This contributed to the annual value of $96.8 million for FY2025, which is 43.99% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Equity Average is $72.0 million, which was down 16.68% from $86.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Equity Average ranged from a high of $444.0 million in Q1 2021 and a low of $72.0 million during Q3 2025.
  • Moreover, its 3-year median value for Equity Average was $157.5 million (2024), whereas its average is $166.1 million.
  • Data for Enanta Pharmaceuticals' Equity Average shows a maximum YoY tumbled of 48.15% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Equity Average stood at $391.9 million in 2021, then fell by 20.62% to $311.1 million in 2022, then plummeted by 34.32% to $204.3 million in 2023, then plummeted by 41.11% to $120.3 million in 2024, then plummeted by 48.15% to $72.0 million in 2025.
  • Its Equity Average was $72.0 million in Q3 2025, compared to $86.4 million in Q2 2025 and $102.7 million in Q1 2025.